
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Access to a financial planner
Recro Pharma is a pharmaceuticals business based in the US. Recro Pharma shares (REPH) are listed on the NASDAQ and all prices are listed in US Dollars.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $1.75 |
200-day moving average | $1.86 |
Wall St. target price | $5.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.26 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Recro Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Recro Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Recro Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8 million.
The EBITDA is a measure of a Recro Pharma's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $75.4 million |
---|---|
Operating margin TTM | 0.55% |
Gross profit TTM | $19.8 million |
Return on assets TTM | 0.2% |
Return on equity TTM | -81.32% |
Profit margin | -15.09% |
Book value | $0.90 |
Market Capitalization | $123.2 million |
TTM: trailing 12 months
We're not expecting Recro Pharma to pay a dividend over the next 12 months.
Recro Pharma's shares were split on a 1115:1000 basis on 21 November 2019 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1115 shares. This wouldn't directly have changed the overall worth of your Recro Pharma shares – just the quantity. However, indirectly, the new 10.3% lower share price could have impacted the market appetite for Recro Pharma shares which in turn could have impacted Recro Pharma's share price.
Over the last 12 months, Recro Pharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recro Pharma's is 1.1154. This would suggest that Recro Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Recro Pharma, Inc. , a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Check out the best-performing ETFs so far in 2025.